Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Filipits

Showing results (81-90 of 122) with videos related to

Pageof 13
Sort By:
Lung Cancer (Amsterdam, Netherlands)|February 16, 2013
PARP1 impact on DNA repair of platinum adducts: preclinical and clinical read-outsKen A Olaussen, Julien Adam, Elsa Vanhecke, et al.
Plos One|March 5, 2013
EVI1 inhibits apoptosis induced by antileukemic drugs via upregulation of CDKN1A/p21/WAF in human myeloid cellsAnna Rommer, Birgit Steinmetz, Friederike Herbst, et al.
Journal of Experimental & Clinical Cancer Research : CR|November 14, 2023
Differential immunomodulatory effects of epirubicin/cyclophosphamide and docetaxel in breast cancer patientsKerstin Wimmer, Monika Sachet, Cristiano Ramos, et al.
European Journal of Cancer (Oxford, England : 1990)|June 6, 2020
The EndoPredict score predicts response to neoadjuvant chemotherapy and neoendocrine therapy in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients from the ABCSG-34 trialPeter C Dubsky, Christian F Singer, Daniel Egle, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|December 7, 2013
Differential survival trends of stage II colorectal cancer patients relate to promoter methylation status of PCDH10, SPARC, and UCHL1Ellen Heitzer, Monika Artl, Martin Filipits, et al.
The New England Journal of Medicine|September 8, 2006
DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapyKen A Olaussen, Ariane Dunant, Pierre Fouret, et al.
Neuro-Oncology|October 31, 2014
Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastomaAnna Sophie Berghoff, Barbara Kiesel, Georg Widhalm, et al.
Breast Cancer Research and Treatment|January 25, 2024
Is the CTS5 a helpful decision-making tool in the extended adjuvant therapy setting?Kerstin Wimmer, Dominik Hlauschek, Marija Balic, et al.
International Journal of Cancer|October 11, 2014
Fatty acid synthase is a metabolic marker of cell proliferation rather than malignancy in ovarian cancer and its precursor cellsDaniel Veigel, Renate Wagner, Gerald Stübiger, et al.
Breast (Edinburgh, Scotland)|February 22, 2025
Validation of the CTS5 in four prospective, multicenter, randomized ABCSG trialsKerstin Wimmer, Dominik Hlauschek, Marija Balic, et al.
Pageof 13

Showing results (81-90 of 122) with videos related to

Sort By:
Pageof 13
Lung Cancer (Amsterdam, Netherlands)|February 16, 2013
PARP1 impact on DNA repair of platinum adducts: preclinical and clinical read-outsKen A Olaussen, Julien Adam, Elsa Vanhecke, et al.
Plos One|March 5, 2013
EVI1 inhibits apoptosis induced by antileukemic drugs via upregulation of CDKN1A/p21/WAF in human myeloid cellsAnna Rommer, Birgit Steinmetz, Friederike Herbst, et al.
Journal of Experimental & Clinical Cancer Research : CR|November 14, 2023
Differential immunomodulatory effects of epirubicin/cyclophosphamide and docetaxel in breast cancer patientsKerstin Wimmer, Monika Sachet, Cristiano Ramos, et al.
European Journal of Cancer (Oxford, England : 1990)|June 6, 2020
The EndoPredict score predicts response to neoadjuvant chemotherapy and neoendocrine therapy in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients from the ABCSG-34 trialPeter C Dubsky, Christian F Singer, Daniel Egle, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|December 7, 2013
Differential survival trends of stage II colorectal cancer patients relate to promoter methylation status of PCDH10, SPARC, and UCHL1Ellen Heitzer, Monika Artl, Martin Filipits, et al.
The New England Journal of Medicine|September 8, 2006
DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapyKen A Olaussen, Ariane Dunant, Pierre Fouret, et al.
Neuro-Oncology|October 31, 2014
Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastomaAnna Sophie Berghoff, Barbara Kiesel, Georg Widhalm, et al.
Breast Cancer Research and Treatment|January 25, 2024
Is the CTS5 a helpful decision-making tool in the extended adjuvant therapy setting?Kerstin Wimmer, Dominik Hlauschek, Marija Balic, et al.
International Journal of Cancer|October 11, 2014
Fatty acid synthase is a metabolic marker of cell proliferation rather than malignancy in ovarian cancer and its precursor cellsDaniel Veigel, Renate Wagner, Gerald Stübiger, et al.
Breast (Edinburgh, Scotland)|February 22, 2025
Validation of the CTS5 in four prospective, multicenter, randomized ABCSG trialsKerstin Wimmer, Dominik Hlauschek, Marija Balic, et al.
Pageof 13